The importance of selecting a proper biological milieu for protein corona analysis in vitro: Human plasma versus human serum.

Nanoparticle (NP) exposure to biological fluids in the body results in protein binding to the NP surface, which forms a protein coating that is called the "protein corona". To simplify studies of protein-NP interactions and protein corona formation, NPs are incubated with biological solutions, such as human serum or human plasma, and the effects of this exposure are characterized in vitro. Yet, how NP exposure to these two different biological milieus affects protein corona composition and cell response has not been investigated. Here, we explore the differences between the protein coronas that form when NPs are incubated in human serum versus human plasma. NP characterization indicated that NPs that were exposed to human plasma had higher amounts of proteins bound to their surfaces, and were slightly larger in size than those exposed to human serum. In addition, significant differences in corona composition were also detected with gel electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry, where a higher fraction of coagulation proteins and complement factors were found on the plasma-exposed NPs. Flow cytometry and confocal microscopy showed that the uptake of plasma-exposed NPs was higher than that of serum-exposed NPs by RAW 264.7 macrophage immune cells, but not by NIH 3T3 fibroblast cells. This difference is likely due to the elevated amounts of opsonins, such as fibrinogen, on the surfaces of the NPs exposed to plasma, but not serum, because these components trigger NP internalization by immune cells. As the human plasma better mimics the composition of the in vivo environment, namely blood, in vitro protein corona studies should employ human plasma, and not human serum, so the biological phenomena that is observed is more similar to that occurring in vivo.

[1]  H. Fuchs,et al.  Reaction of human macrophages on protein corona covered TiO₂ nanoparticles. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[2]  Ching-Seng Ang,et al.  Monoclonal antibody-functionalized multilayered particles: targeting cancer cells in the presence of protein coronas. , 2015, ACS nano.

[3]  Weihong Tan,et al.  Fluorescent nanoparticles for multiplexed bacteria monitoring. , 2007, Bioconjugate chemistry.

[4]  Dan Peer,et al.  Nanoparticle hydrophobicity dictates immune response. , 2012, Journal of the American Chemical Society.

[5]  Analysis of macrophage phagocytosis: quantitative assays of phagosome formation and maturation using high-throughput fluorescence microscopy. , 2009, Methods in molecular biology.

[6]  M. Grzelczak,et al.  Glycans as biofunctional ligands for gold nanorods: stability and targeting in protein-rich media. , 2015, Journal of the American Chemical Society.

[7]  Wenwan Zhong,et al.  Size and Surface Functionalization of Iron Oxide Nanoparticles Influence the Composition and Dynamic Nature of Their Protein Corona , 2014, ACS applied materials & interfaces.

[8]  C. Mirkin,et al.  Spherical nucleic acid nanoparticle conjugates enhance G-quadruplex formation and increase serum protein interactions. , 2014, Angewandte Chemie.

[9]  K. Kwiatkowska,et al.  Binding of IgG-Opsonized Particles to FcγR Is an Active Stage of Phagocytosis That Involves Receptor Clustering and Phosphorylation1 , 2005, The Journal of Immunology.

[10]  J. Vallée,et al.  Ex situ evaluation of the composition of protein corona of intravenously injected superparamagnetic nanoparticles in rats. , 2014, Nanoscale.

[11]  Marilena Hadjidemetriou,et al.  In Vivo Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid Bilayer Nanoscale Vesicles. , 2015, ACS nano.

[12]  Iseult Lynch,et al.  Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.

[13]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[14]  K. Dawson,et al.  Time and space resolved uptake study of silica nanoparticles by human cells. , 2011, Molecular bioSystems.

[15]  Paolo Bergese,et al.  Surfactant titration of nanoparticle-protein corona. , 2014, Analytical chemistry.

[16]  P. Charoenphol,et al.  Plasma Protein Corona Modulates the Vascular Wall Interaction of Drug Carriers in a Material and Donor Specific Manner , 2014, PloS one.

[17]  Timothy D Veenstra,et al.  Serum and plasma proteomics. , 2007, Chemical reviews.

[18]  Iseult Lynch,et al.  The evolution of the protein corona around nanoparticles: a test study. , 2011, ACS nano.

[19]  Kenneth A. Dawson,et al.  Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.

[20]  G. J. Cannon,et al.  The macrophage capacity for phagocytosis. , 1992, Journal of cell science.

[21]  Parag Aggarwal,et al.  Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[22]  M. Mahmoudi,et al.  Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. , 2016, Biomaterials.

[23]  M. Mann,et al.  Exponentially Modified Protein Abundance Index (emPAI) for Estimation of Absolute Protein Amount in Proteomics by the Number of Sequenced Peptides per Protein*S , 2005, Molecular & Cellular Proteomics.

[24]  E. Peterhans,et al.  Fibrinogen association with human monocytes: evidence for constitutive expression of fibrinogen receptors and for involvement of Mac-1 (CD18, CR3) in the binding. , 1988, Biochemical and biophysical research communications.

[25]  Jin Xie,et al.  Nanoparticle-based theranostic agents. , 2010, Advanced drug delivery reviews.

[26]  Warren C W Chan,et al.  Nanoparticle-blood interactions: the implications on solid tumour targeting. , 2015, Chemical communications.

[27]  Iseult Lynch,et al.  Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Karen L Wooley,et al.  Design of polymeric nanoparticles for biomedical delivery applications. , 2012, Chemical Society reviews.

[29]  Kenneth A Dawson,et al.  Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. , 2013, Journal of the American Chemical Society.

[30]  P. Mannucci,et al.  Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen , 1988, The Journal of cell biology.

[31]  Stefan Tenzer,et al.  Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.

[32]  K. Higaki,et al.  Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. , 2007, International journal of pharmaceutics.

[33]  K. Dawson,et al.  Characterization of the bionano interface and mapping extrinsic interactions of the corona of nanomaterials. , 2015, Nanoscale.

[34]  Jianjun Cheng,et al.  Protein corona significantly reduces active targeting yield. , 2013, Chemical communications.

[35]  Bo Yan,et al.  Fabrication of Corona-Free Nanoparticles with Tunable Hydrophobicity , 2014, ACS nano.

[36]  Philip M. Kelly,et al.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.

[37]  Zhengping Zhang,et al.  Corona-directed nucleic acid delivery into hepatic stellate cells for liver fibrosis therapy. , 2015, ACS nano.

[38]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Warren C W Chan,et al.  Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. , 2012, Chemical Society reviews.

[40]  L. Leive,et al.  Variants deficient in phagocytosis of latex beads isolated from the murine macrophagelike cell line J774 , 1984, The Journal of cell biology.

[41]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[42]  Sara Linse,et al.  Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[43]  M. Mahmoudi,et al.  Protein-nanoparticle interactions: opportunities and challenges. , 2011, Chemical reviews.

[44]  Sara Linse,et al.  Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. , 2007, Angewandte Chemie.

[45]  A. S. Moses,et al.  Imaging and drug delivery using theranostic nanoparticles. , 2010, Advanced drug delivery reviews.

[46]  James Chen Yong Kah,et al.  Optimizing the properties of the protein corona surrounding nanoparticles for tuning payload release. , 2013, ACS nano.

[47]  B. Forbes,et al.  Surface chemistry of photoluminescent F8BT conjugated polymer nanoparticles determines protein corona formation and internalization by phagocytic cells. , 2015, Biomacromolecules.

[48]  M. Hashida,et al.  Important role of serum proteins associated on the surface of particles in their hepatic disposition. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[49]  Warren C W Chan,et al.  The effect of nanoparticle size, shape, and surface chemistry on biological systems. , 2012, Annual review of biomedical engineering.

[50]  Li Tang,et al.  Synthesis and biological response of size-specific, monodisperse drug-silica nanoconjugates. , 2012, ACS nano.

[51]  Kenneth A Dawson,et al.  Suppression of nanoparticle cytotoxicity approaching in vivo serum concentrations: limitations of in vitro testing for nanosafety. , 2014, Nanoscale.

[52]  Murali M. Yallapu,et al.  Implications of protein corona on physico-chemical and biological properties of magnetic nanoparticles. , 2015, Biomaterials.

[53]  Kenneth A. Dawson,et al.  Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. , 2012, ACS nano.

[54]  Morteza Mahmoudi,et al.  Cell "vision": complementary factor of protein corona in nanotoxicology. , 2012, Nanoscale.

[55]  Iseult Lynch,et al.  What the cell "sees" in bionanoscience. , 2010, Journal of the American Chemical Society.

[56]  P. Ralph,et al.  Functional macrophage cell lines transformed by abelson leukemia virus , 1978, Cell.